通过调节细胞死亡途径,CD44变体外基因诱导化学抵抗.
Maria Yanova1, Evgeniya Stepanova1, Diana Maltseva1
1Faculty of Biology and Biotechnology, National Research University Higher School of Economics, Moscow, Russia.
Frontiers in cell and developmental biology
|March 21, 2025
概括
癌症化学抵抗是一个主要的挑战,但CD44变体外因子正在成为关键参与者. 了解它们在细胞死亡途径中的作用为向癌症治疗提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 癌症中的化学抵抗导致治疗失败.
- CD44是一种细胞表面糖蛋白,与癌症生物学有关.
- CD44变体外因子与化学抵抗和癌症进展有关.
研究的目的:
- 分析CD44变异异构与患者化疗结果的相关性.
- 探索CD44变异异构体在调节癌细胞死亡途径中的作用.
- 审查针对CD44变体外体异型的临床试验.
主要方法:
- 关于CD44变体外型和临床结果的综合文献综述.
- 分析CD44在亡,铁亡和自中的作用.
- 检查针对CD44的治疗策略和临床试验.
主要成果:
- 特定的CD44变异外型 (例如v6,v9) 显著影响患者化疗结果.
- CD44变体外因子调节关键细胞死亡途径,影响药物耐药性.
- 变异性含有外体的CD44异型与临床结果有关.
结论:
- CD44变体外型是化学抵抗和患者预后的关键决定因素.
- 向CD44变异异位异型的异位异型是一种有前途的治疗策略.
- 对CD44向治疗的进一步研究可以克服癌症药物耐药性的问题.
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
The Extrinsic Apoptotic Pathway
5.7K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
5.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
The Intrinsic Apoptotic Pathway
5.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.8K


